A quarter where shrinking revenue is the point
UnitedHealth Group publishes third-quarter 2026 results before the US open on Tuesday 13 October, with a conference call at 8:00 a.m. Eastern time, according to the company's own announcement of 15 September. The morning is busy: JPMorgan and the large banks report alongside, as does Johnson & Johnson, placing healthcare's two biggest companies on the same tape.
The unusual feature of this print is the shape of the numbers. Revenue is expected to fall while profit climbs sharply. That combination is not an accident. After the cost shock of 2025, UnitedHealth deliberately shed members, repriced plans and exited unprofitable arrangements, and is now attempting to earn more on a smaller book of business.
The consensus and what it implies
Zacks Investment Research data, as displayed on Nasdaq's earnings page, shows eight analysts expecting adjusted earnings of $4.12 a share, in a range of $4.01 to $4.56. The comparable figure a year earlier was $2.92, so the consensus implies growth of roughly 41%. The revenue estimate on FMP is $111.3 billion, about 1.7% below the $113.2 billion recorded in the third quarter of 2025.
The share price already reflects a decent outcome. UnitedHealth closed on Friday 9 October at $379.30, which is 14.9% above the $330.11 close of 31 December 2025, yet 13.1% below the 2026 closing high of $436.35 set on 21 July, five days after management lifted the full-year outlook.
The ratio that decides the reaction
The medical care ratio, the share of premiums paid out in claims, is the single line that frames the quarter. The series has been volatile, and the guided target leaves limited room for error in the seasonally heavier half of the year.
| Period | Medical care ratio |
|---|---|
| Q3 2025 | 89.9% |
| Q4 2025 | 92.4% |
| Q1 2026 | 83.9% |
| Q2 2026 | 86.7% |
| 2026 guidance | 88.1% plus or minus 25 basis points |
The second-quarter figure included $860 million of favourable reserve development, mostly tied to 2026 dates of service, meaning claims arrived below what had been booked earlier in the year. The ratio normally rises as members meet deductibles, so a step up from the second quarter is expected rather than alarming.
The arithmetic is straightforward. If premium revenue is broadly even across quarters, a full-year 88.1% after a first half averaging about 85.3% implies a second half near 90.9%. A third-quarter reading around 90%, roughly flat against last year's 89.9%, would sit comfortably with guidance. A figure clearly above 91% would force an unusually benign fourth quarter, and that is the version of events the market would punish.
Management language deserves equal attention. In April the company described utilisation and unit cost trends as "consistently elevated". Improvement has come from pricing, benefit reductions and exits rather than from lower healthcare usage, which makes commentary on trend more informative than the headline percentage.
Guidance arithmetic for the second half
On 16 July UnitedHealth raised its 2026 adjusted EPS outlook to $19.50–20.00 from "greater than $17.75" in January, and its GAAP outlook to $18.45–18.95. The first half produced $7.23 and $6.38, or $13.61 combined, leaving an implied $5.89–6.39 for the remainder of the year.
The Zacks consensus for the third and fourth quarters totals $6.25, in the upper part of that implied range, while the full-year consensus of $19.85 sits close to the top of guidance. Other guided metrics moved too: operating cash flow of about $24 billion against "more than $18 billion" previously, and buybacks of "at least $5 billion" instead of roughly $2.5 billion.
Medicare Advantage: smaller by design, tighter by policy
UnitedHealthcare covered 7.565 million Medicare Advantage members at the end of June, down 880,000 from 8.445 million at the close of 2025. Total medical membership was 48.5 million, around 1.2 million lower, while fee-based commercial membership added 780,000. January's plan called for Medicare Advantage to contract by 1.15–1.2 million across the year.
The policy backdrop is unforgiving. On 27 January the Centers for Medicare & Medicaid Services proposed a 0.09% payment increase for 2027 Medicare Advantage plans, far below the 4–6% analysts anticipated. The stock fell 19.6% that day, from $351.64 to $282.70, and marked its 2026 low close of $259.02 on 27 March. On 1 October the company introduced 2027 Medicare plans, stating that about 90% of eligible consumers with access to a UnitedHealthcare plan will have a $0 premium option.
Optum remains the unfinished part
Optum Health revenue declined 5% in the second quarter to $23.5 billion, with roughly 700,000 fewer patients in value-based care arrangements and an operating margin of 5.1%. Optum Rx generated $38.3 billion of revenue at a 3.9% margin, with adjusted scripts falling to 387 million from 414 million. Optum Insight delivered a 25.3% margin on $5.4 billion of revenue.
Optum Health is where the recovery case is least proven. The value-based care book was cut back after loss-making contracts were reserved against in the fourth quarter of 2025, so margin direction rather than patient counts is the relevant signal.
Credibility earned, credibility tested
Stephen Hemsley returned as chief executive in May 2025, when guidance was suspended as medical costs overshot plan. The year closed with an adjusted medical care ratio of 88.9%, up 340 basis points from 85.5% in 2024, alongside a $1.6 billion after-tax charge in the fourth quarter. Since then the company has set conservative targets and raised them twice, to "greater than $18.25" in April and to $19.50–20.00 in July.
Analysts tracked by S&P Global, as shown on StockAnalysis, carry an average price target of $480.60, with the shares at about 17.8 times forward earnings on the same data. A beat paired with an unchanged range would leave second-half implied figures looking undemanding; a third raise would confirm deliberate conservatism.
Three ways Tuesday can go
A beat and raise means adjusted EPS above $4.12, a ratio near 90% and a lifted bottom of the range, which is closest to what the 15% year-to-date gain assumes. A beat and hold leaves EPS above consensus and guidance reiterated, which reads cautious rather than negative but may let the stock drift. A cost surprise means a ratio well above 91% or renewed acceleration in trend.
In analyst Ruslan Averin's view, the third-quarter ratio and the tone on 2027 Medicare Advantage margins will determine the share price reaction far more than the earnings figure itself, since enrolment is open and early membership signals matter now. The company has built goodwill in 2026 by under-promising; Tuesday tests whether that holds in the harder half of the year.